Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol

<p><strong>Objective:</strong> PCSK9 inhibitors have been shown to reduce LDLc by up to about 60% and 85% when used with high doses of statins and ezetimibe (2019 ESC/EAS Guidelines). These therapies may lead to very low levels of LDLc and have been associated with possible cognitive deteriora...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	José Seijas-Amigo, Diego Rodríguez-Penas, Ana Estany-Gestal, Pedro Suárez-Artime, María Santamaría-Cadavid, José Ramón González-Juanatey
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2021-05-01
Ráidu:	Farmacia Hospitalaria
Fáttát:	alirocumab evolocumab pcsk9 inhibitors cholesterol cognition lipid-lowering therapies
Liŋkkat:	http://www.aulamedica.es/fh/pdf/11569.pdf
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!